1/29
10:00 am
til
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
1/27
01:20 pm
til
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
1/22
10:00 am
til
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
1/20
01:33 pm
til
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
1/15
10:00 am
til
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
1/13
04:02 pm
til
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
1/8
10:16 pm
til
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
1/6
08:17 am
til
Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco [Yahoo! Finance]
High
Report
Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco [Yahoo! Finance]
1/6
07:00 am
til
Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco
High
Report
Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco
11/13
07:00 am
til
Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Medium
Report
Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update